Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Center, Korea
NRG Oncology
Mayo Clinic
Janssen Research & Development, LLC
UroGen Pharma Ltd.
Aarhus University Hospital
Hospital Centre Biel/Bienne
UroGen Pharma Ltd.
Tongji Hospital
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)